These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34589150)

  • 1. Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma.
    Chen R; Wang Y; Li T; Lv J; Feng G; Tan N; Wang J; Cheng X
    Oncol Lett; 2021 Nov; 22(5):771. PubMed ID: 34589150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of imaging and pathology features of mucinous carcinoma of the breast.
    Zhang L; Jia N; Han L; Yang L; Xu W; Chen W
    Clin Breast Cancer; 2015 Apr; 15(2):e147-54. PubMed ID: 25523373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of the sub-classification of 71 cases mucinous breast carcinoma.
    Kashiwagi S; Onoda N; Asano Y; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
    Springerplus; 2013; 2():481. PubMed ID: 24156087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014).
    Pan B; Yao R; Shi J; Xu QQ; Zhou YD; Mao F; Lin Y; Guan JH; Wang XJ; Zhang YN; Zhang XH; Shen SJ; Zhong Y; Xu YL; Zhu QL; Liang ZY; Sun Q
    Oncotarget; 2016 Jun; 7(25):38864-38875. PubMed ID: 27102151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
    Wang W; Chen X; Lin L; Fei X; Garfield DH; Hong J; Gao W; Zhu S; Wu J; Huang O; He J; Li Y; Zhu L; Chen W; Shen K
    J Cancer; 2018; 9(18):3216-3224. PubMed ID: 30271480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics and prognosis of mucinous breast carcinoma.
    Zhang M; Teng XD; Guo XX; Zhao JS; Li ZG
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):265-9. PubMed ID: 24305754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
    Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
    Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
    Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure and Mixed Mucinous Carcinoma of the Breast: A Comparison of Clinical Outcomes and Treatment Results.
    Skotnicki P; Sas-Korczynska B; Strzepek L; Jakubowicz J; Blecharz P; Reinfuss M; Walasek T
    Breast J; 2016 Sep; 22(5):529-34. PubMed ID: 27261206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-lesion histogram analysis of the apparent diffusion coefficient: Evaluation of the correlation with subtypes of mucinous breast carcinoma.
    Guo Y; Kong QC; Zhu YQ; Liu ZZ; Peng LR; Tang WJ; Yang RM; Xie JJ; Liu CL
    J Magn Reson Imaging; 2018 Feb; 47(2):391-400. PubMed ID: 28640538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
    Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients.
    Huang Z; Qin Q; Xia L; Lian B; Tan Q; Yu Y; Mo Q
    Cancer Manag Res; 2021; 13():587-593. PubMed ID: 33519238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Effective Ultrasound Features-Based Diagnostic Model via Principal Component Analysis Facilitated Differentiating Subtypes of Mucinous Breast Cancer From Fibroadenomas.
    Zhang L; Wang L; Liang R; He X; Wang D; Sun L; Yu S; Su W; Zhang W; Zhou Q; Wang J; Jiang J
    Clin Breast Cancer; 2024 Oct; 24(7):e583-e592.e3. PubMed ID: 38871576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
    Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
    Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
    Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
    Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
    Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.